Results 31 to 40 of about 100,362 (316)

Preparation of a nanovaccine against Brucella melitensis M16 based on PLGA nanoparticles and oligopolysaccharide antigen

open access: yesArtificial Cells, Nanomedicine, and Biotechnology, 2019
Brucellosis is one of the most common and important diseases between humans and animals. Herein, we developed a nanovaccine against Brucella melitensis based on oligopolysaccharide (OPS) antigen and PLGA nanoparticles.
Masoud Maleki   +3 more
doaj   +1 more source

Vaccine-Preventable Haemophilus influenza Type B Disease Burden and Cost-Effectiveness of Infant Vaccination in Indonesia [PDF]

open access: yes, 2008
Background: Most of Asia, including Indonesia, does not use Haemophilus influenzae type b (Hib) conjugate vaccines. We estimated total vaccine-preventable disease burden and the cost-effectiveness of Hib conjugate vaccine in Indonesia.
Walker, Damian G   +9 more
core   +1 more source

Pneumococcal carriage in sub-Saharan Africa--a systematic review. [PDF]

open access: yes, 2014
BACKGROUND: Pneumococcal epidemiology varies geographically and few data are available from the African continent. We assess pneumococcal carriage from studies conducted in sub-Saharan Africa (sSA) before and after the pneumococcal conjugate vaccine (PCV)
Bottomley, Christian   +15 more
core   +1 more source

The Synthesis and Preliminary Anticancer Evaluation of 6-Mercaptopurine -Methotrexate Conjugate as Possible Mutual Prodrug

open access: yesIraqi Journal of Pharmaceutical Sciences, 2019
Small molecules drug conjugate mutual prodrug design  (SMDC) composed of folate &lethal agent conjugate  , rigidly bonded via hydrophilic bridge& self immolative disulfide  bond   ;  represent new interesting approaches for cancer treatment , the ...
Asmaa Safwan Al-darraji   +1 more
doaj   +1 more source

Costs of vaccine delivery in the Gambia before and after, pentavalent and pneumococcal conjugate vaccine introductions.

open access: yes, 2014
BACKGROUND: The Gambia introduced seven-valent pneumococcal conjugate vaccine (PCV) in August 2009 and switched to 13-valent PCV in April 2011. In April 2009 monovalent hepatitis B and combined Diphtheria-Tetanus-Pertussis and Haemophilus influenzae type
Lowe-Jallow, Y   +6 more
core   +1 more source

Health‐Related Quality of Life and Symptom Severity Among Patients With PIK3CA‐Related Overgrowth Spectrum: A Mixed‐Methods Study to Understand Real‐World Experience With Alpelisib Treatment

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background PIK3CA‐related overgrowth spectrum (PROS) includes several rare overgrowth disorders resulting from somatic gain‐of‐function mutations in PIK3CA. Despite treatment advances, including the recent approval of alpelisib for PROS in the United States, literature detailing the patient experience with PROS is limited.
Vamsi Bollu   +8 more
wiley   +1 more source

Data set on the synthesis and properties of 2′,3′-dideoxyuridine triphosphate conjugated to SiO2 nanoparticles

open access: yesData in Brief, 2018
SiO2 nanoparticles were used as a transport system for cellular delivery of phosphorylated 2′,3′-dideoxyuridine to increase its anticancer potency. This data set is related to the research article entitled “2′,3′-Dideoxyuridine triphosphate conjugated to
Svetlana V. Vasilyeva   +3 more
doaj   +1 more source

A Novel Curcumin-Mycophenolic Acid Conjugate Inhibited Hyperproliferation of Tumor Necrosis Factor-Alpha-Induced Human Keratinocyte Cells

open access: yesPharmaceutics, 2021
Curcumin (CUR) has been used as adjuvant therapy for therapeutic application in the treatment of psoriasis through several mechanisms of action.
Yonelian Yuyun   +7 more
doaj   +1 more source

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman   +7 more
wiley   +1 more source

Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”

open access: yesHuman Vaccines & Immunotherapeutics, 2019
In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico.
Matt Wasserman   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy